Subscribe
dmitrii-guzhanin-istockphoto-com-scales--1
Dmitrii_Guzhanin / iStockphoto.com
18 January 2018Europe

Mixed views on Broad’s fate after EPO revokes CRISPR patent

Commentators have offered differing opinions on the impact of yesterday’s decision by the European Patent Office (EPO) to revoke a CRISPR/Cas9 patent owned by the Broad Institute of Harvard and MIT.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Cambridge University signs partnership to address innovation challenges
30 January 2018   The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Biotechnology
Cambridge University signs partnership to address innovation challenges
30 January 2018   The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.

More on this story

Biotechnology
Cambridge University signs partnership to address innovation challenges
30 January 2018   The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner